Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium Falciparum Malaria

NCT06040346 is registered in ClinicalTrials.gov with Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd as lead sponsor.

NCT NCT06040346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06040346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium Falciparum Malaria
Lead sponsor
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 26, 2024
Completion date
October 9, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria